DOCSLIB.ORG

Book of Abstracts of Gynecological Endocrinology the 19Th World Congress

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Book of Abstracts of Gynecological Endocrinology the 19Th World Congress SUPPLEMENT 1 Book of abstracts of Gynecological Endocrinology the 19th World Congress WWW.GREMJOURNAL.COM VOLUME 1 • SUPPLEMENT 1 • 2020 Fertility nspired by nature IBSA Institut Biochimique SA Via del Piano 29, 6915 Lugano, Switzerland www.ibsagroup.com ADV20_FertilityLine_Final.indd 1 02.03.20 15:35 VOLUME 1 • SUPPLEMENT 1 • 2020 Editor In Chief Andrea R. Genazzani (IT) Editorial Board Leila Adamyan Efthimios Deligeoroglou Pauline Maki Joseph Schenker Farook Al-Azawi Gian Carlo Di Renzo Paolo Mannella Adolf Schindler Stefano Angioni Marie-Madeleine Dolmans Takeshi Maruo Michael Schumacher David Archer Jacques Donnez Tamaki Matsumoto John J. Sciarra Jean-Francois Arnal Rene Druckman Blazej Meczekalski David Serfaty Paolo Artini Fabio Facchinetti Jose Mendez Ribas Duru Shah Edmund Baracat Dov Feldberg Maria Cristina Meriggiola Carlos Simon Eytan Barnea Xiaodong Fu Joannis Messinis Tommaso Simoncini Pedro Barri Tomoyuki Fujii Andrzej Milewicz Christian Singer Patricio Barriga Luis Miguel Garcia Segura Edgar Mocanu Nestor Siseles Chiara Benedetto Kristina Gemzell Danielsson Patrizia Monteleone Regine Sitruk-Ware Sarah Berga Alessandro Genazzani Philippe Morice Sven Skouby Nicoletta Biglia Sandro Gerli Alfred Mueck Antonina Smetnik Martin Birkhaeuser Andrea Giannini Frederick Naftolin John Stevenson Johannes Bitzer Dimitrios Goulis Rossella Nappi Jerome Strauss J.F Edoardo Borges Da Fonseca Alessandra Grazziottin Jose Luis Neyro Charles Sultan Mark Brincat Angelica Hirshberg Linden Michelle Nisolle Basil Tarlatzis Roberta Brinton Diaz Moshe Hod Santiago Palacios Hugh Taylor Pavel Calda Ludwig Kiesel Nick Panay Robert Taylor Antonio Cano Sanja Kupesic Antonio Pellicer Ekaterine Tskitishvili Howard Carp Antonio La Marca Faustino Perez Lopez Filippo Ubaldi Salvatore Caruso Michele Lachowsky Felice Petraglia Richard Van Lunsen Cuauhtemoc Celis Irene Lambrinoudaki Nicola Pluchino Michael Van Trotsenburg Frederique Chantraine Stefano Lello Jean-Yves Reginster Anna Veiga Peter Chedraui Rogerio Lobo Alberto Revelli Gary Ventolini George Creatsas Patrice Lopes Walter Rocca Svetlana Vujovic Emile Darai Stefano Luisi Xiangyan Ruan Antoine Watrelot Nilson Roberto De Melo Mario Maggi Camilo Rueda Tevfik Yoldemir Publication management Feto-Maternal Medicine, Basic Science, Instructions for Authors BTpress Pharmacology, Epidemiology, Metabo- You can find instructions for submitting www.btcongress.com lism, Oncology, Neuro-Endocrinology manuscripts at: Editorial Manager Psycho-Somatic Medicine,Sexology, Fe- www.gremjournal.com/instructions/ Manuscripts should be submitted using Anna Kamola male Aging, Ethics, Quality of Life and any the on-line submission and manuscript other aspects of Gynecological and Repro- Production Office tracking system at: ductive Endocrinology and Metabolism. MediMay Communication Srl www.gremjournal.com/submit-an-article/ In particular articles related to Endocrine Via Giovanni Antonelli, 47 Warning to readers Therapies in women, Puberty, Adolescent 00139 Rome, Italy The Publisher declines all responsibility Gynecology, Contraception, Fertility, Po- [email protected] deriving from errors or omissions regard- The Journal lycystic Ovary, Endometriosis, Assist- ing the dosage and use of products possibly Gynecological and Reproductive Endo- ed Reproduction, Abortion, Eclampsia, mentioned in the articles, and invites the crinology and Metabolism, an Open-Ac- Gestational Diabetes Mellitus, Premature reader to personally check the accuracy, cess Journal of the ISGE, will publish Labor, Breast Feeding, Premature Ova- referring to the relative bibliography. Editorials, Statements, Position Papers, rian Insufficiency, Menopause, Female Address for correspondence Systematic Reviews, Meta-analysis, Short- Sexual Dysfunction, Osteoporosis, GSM/ Andrea R. Genazzani: Reviews, Ori ginal Articles and Case Re- VVA and any other topics related to Gy- [email protected] ports on the research area of the fields necological and Reproductive Endocri- Anna Kamola: [email protected] of Gynecology, Obstetrics, Reproduction, nology and Metabolism will be welcome. BTpress: [email protected] Copyright © - 2020 - International Society of Gynecological Endocrinology (ISGE) GREM is published quarterly in March, June, September and December by International Society of Gynecological Endocrinology INDEX 5 Editorial 6 Key Lectures 14 Symposia 62 Meet the Experts 73 Scholarship Courses 83 Scientific Societies Symposia 117 Oral Presentations 340 Poster Session 648 Sponsored Key Lectures 651 Sponsored Meet the Experts 654 Sponsored Symposia 660 Author index 4 Gynecological and Reproductive Endocrinology and Metabolism 2020; Supplement 1 – Book of asbtracts EDITORIAL Dear Friends For all Executive Committee of the International Society of GREM, includes all received abstracts of Key Lectures, Sympo- Gynecological Endocrinology is a pleasure to introduce the sia, Meet the Experts, Scientific Societies Symposia, 249 Oral Abstract Book of the 19th World Congress of Gynecological presentations, 350 Posters and the abstracts of the sessions or- Endocrinology (On Line Congress 2-5 December 2020, avail- ganized by our Sponsors. able until 15 April 2012) as Supplementum n. 1 of our New This volume contains also the abstracts of the Lectures of the Open-Access Journal: GREM – Gynecological and Reproduc- ISGE Scholarship Special Course for trainees and Post-Doc tive Endocrinology and Metabolism. who participated in our Scholarship Program. This represents a further effort of ISGE to promote investiga- We invite all of you to go to the third cover page of this book tions and education in Gynecological Endocrinology. GREM is and to accept our invitation: GREM is looking for your Manu- the demonstration of the vitality and worldwide engagement of script! ISGE to stimulate the upgrading of Gynecologists and Obste- I would like to express our gratitude to Peter Chedraui as Editor tricians in Gynecological and Reproductive Endocrinology and in Chief since January 2020 of our first journal: Gynecological Metabolism. Endocrinology, who started in March 1987, edited by Taylor The New Open-access GREM, edited by ISGE in collaboration and Francis, successfully growing as quality and number of pa- with BTpress and Medimay will publish all kind of papers: Ed- pers received and published. itorials, Statements, Position Papers, Reviews, Meta-analyses, With this in mind, I wish for all of you to enjoy the on-line par- Original Articles and Case Reports covering all areas of Gy- ticipation to the19th World Congress of Gynecological Endocri- necological, Obstetrical and Reproductive Endocrinology, and nology to enrich your culture and your knowledge in this fantas- Metabolism. tic discipline who covers areas of fundamental importance for The 19th World Congress Abstract Book, as Supplement n. 1 of women health and quality of life. Andrea R. Genazzani President of ISGE 5 Gynecological and Reproductive Endocrinology and Metabolism 2020; Supplement 1 – Book of asbtracts Key Lectures Key Lectures (KL02) The human yolk sac, perhaps the most important transient organ The human yolk sac, perhaps the most important transient organ Frederick Naftolin (US) Department of Obstetrics and Gynecology, New York University Grossman School of Medicine, New York, USA The human embryo-fetus develops several transient organs. These include the placenta, the fetal adrenal reticular zone and the yolk sac. While the first two are well-documented and studied, the yolk sac is generally only thought of as the source of endodermal mesenchymal precursor cells. Its early origins in the blastula are unstudied except for anatomic specimens that are characterized in a comparative biology context. Yet, the direct inclusion by the pincer-like action of the developing amniotic sac in the body of the embryo of the dorsal part of the (primary) yolk sac includes much of the precursors of the gut, blood and vessels and other systems in the corpus of the developing embryo-fetus. More such stem elements enter via the vitelline vessels before the (secondary) yolk sac is eclipsed and shunted off to the edges of the developing chorion-amnion interface. With the availability of high-resolution ultrasound, there has been a resurgence of studies on the morphology of the secondary yolk sac, primarily as a harbinger of the health of the developing embryo-fetus. Animal studies have shown the importance of the yolk sac in development. For example, comparatively small changes in glucose levels result in the increase in fetal anomalies that plagued the offspring of uncontrolled diabetics. Tight glucose control has reduced the rate of anomalies of diabetic pregnancies to less than that of normal pregnancies. With the availability of cells removed from embryos in vitro and dated products of conception from failed in vitro fertilization cases, the opportunity to properly study the yolk sac has arisen. Scientific study of this important transient organ should be a high priority in the coming decade. 7 Gynecological and Reproductive Endocrinology and Metabolism 2020; Supplement 1 – Book of asbtracts Key Lectures (KL06) Translational research with thyroid hormone in the placenta Translational research with thyroid hormone in the placenta Takeshi Maruo (JP) Kobe Children’s Hospital Clinically it is known that hypothyroidism is one of the endocrine factors for early pregnancy loss. Corpus luteum is the prime source of P4 production in very early pregnancy, and placenta takes over the corpus luteum function at 6- week of pregnancy.
Load more

Recommended publications
  • Donatella Feat. Rettore
    DONATELLA FEAT. RETTORE: Giovedì 25 giugno 2015 – ore 00.00 GAY VILLAGE 2015 Dal 18 giugno al 12 settembre 2015 Ingresso gratuito dalle 19.00 alle 21.00 Roma Eur - Parco del Ninfeo - Via delle Tre Fontane www.gayvillage.it 22/06/2015 Giovedì 25 giugno 2015 – ore 00.00 Dopo la vittoria de L'Isola dei Famosi Le DONATELLA dedicano a tutti i fan e al pubblico Gay Village DONATELLA FEAT. RETTORE produced and arranged by Tommy Vee, Mauro Ferrucci, Keller & Crossfingers supervised and realized by Mattia Guerra for Agidi srl IN TUTTI I DIGITAL STORE E DOPO IL SINGOLO ARRIVA LA DONADANCE: Chissà come sarebbe andata se fossero rimaste le Provs Destination. Non lo sapremo mai perché nella sesta edizione del talent show X Factor, l'allora giudice Arisa aveva intuito che le giovanissime sorelle gemelle Giulia e Silvia Provvedi avevano non solo un innato talento per il mondo dello spettacolo, ma anche un punto di riferimento nel firmamento musicale italiano: Donatella Rettore. Da quel momento le allora 18enni modenesi divennero le Donatella. Vincitrici dell'ultima trionfale edizione de L'Isola dei Famosi, le Donatella si lanciano con il loro incontenibile entusiasmo in questo nuovo progetto, il brano Donatella: "Non lo vediamo come un singolo vero e proprio ma come un divertimento in musica, un regalo a tutti i nostri fan in perfetto stile Donatella: energico, pieno di vita e travolgente!" Con questa scelta vogliono naturalmente rendere omaggio alla regina del synth pop anni '80 che ha ispirato il loro nome d'arte: Donatella Rettore. "Per noi si realizza un sogno -? dichiarano: abbiamo sempre desiderato conoscere Donatella Rettore e finalmente ce l'abbiamo fatta! Questo progetto ci riempie di orgoglio: una rivisitazione moderna in chiave dance del famoso brano del 1981, che abbiamo sempre amato moltissimo per la sua ironia e sregolatezza.
    [Show full text]
  • Aldrich FT-IR Collection Edition I Library
    Aldrich FT-IR Collection Edition I Library Library Listing – 10,505 spectra This library is the original FT-IR spectral collection from Aldrich. It includes a wide variety of pure chemical compounds found in the Aldrich Handbook of Fine Chemicals. The Aldrich Collection of FT-IR Spectra Edition I library contains spectra of 10,505 pure compounds and is a subset of the Aldrich Collection of FT-IR Spectra Edition II library. All spectra were acquired by Sigma-Aldrich Co. and were processed by Thermo Fisher Scientific. Eight smaller Aldrich Material Specific Sub-Libraries are also available. Aldrich FT-IR Collection Edition I Index Compound Name Index Compound Name 3515 ((1R)-(ENDO,ANTI))-(+)-3- 928 (+)-LIMONENE OXIDE, 97%, BROMOCAMPHOR-8- SULFONIC MIXTURE OF CIS AND TRANS ACID, AMMONIUM SALT 209 (+)-LONGIFOLENE, 98+% 1708 ((1R)-ENDO)-(+)-3- 2283 (+)-MURAMIC ACID HYDRATE, BROMOCAMPHOR, 98% 98% 3516 ((1S)-(ENDO,ANTI))-(-)-3- 2966 (+)-N,N'- BROMOCAMPHOR-8- SULFONIC DIALLYLTARTARDIAMIDE, 99+% ACID, AMMONIUM SALT 2976 (+)-N-ACETYLMURAMIC ACID, 644 ((1S)-ENDO)-(-)-BORNEOL, 99% 97% 9587 (+)-11ALPHA-HYDROXY-17ALPHA- 965 (+)-NOE-LACTOL DIMER, 99+% METHYLTESTOSTERONE 5127 (+)-P-BROMOTETRAMISOLE 9590 (+)-11ALPHA- OXALATE, 99% HYDROXYPROGESTERONE, 95% 661 (+)-P-MENTH-1-EN-9-OL, 97%, 9588 (+)-17-METHYLTESTOSTERONE, MIXTURE OF ISOMERS 99% 730 (+)-PERSEITOL 8681 (+)-2'-DEOXYURIDINE, 99+% 7913 (+)-PILOCARPINE 7591 (+)-2,3-O-ISOPROPYLIDENE-2,3- HYDROCHLORIDE, 99% DIHYDROXY- 1,4- 5844 (+)-RUTIN HYDRATE, 95% BIS(DIPHENYLPHOSPHINO)BUT 9571 (+)-STIGMASTANOL
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Menstrually Related and Nonmenstrual Migraines in A
    MENSTRUALLY RELATED AND NONMENSTRUAL MIGRAINES IN A FREQUENT MIGRAINE POPULATION: FEATURES, CORRELATES, AND ACUTE TREATMENT DIFFERENCES A dissertation presented to the faculty of the College of Arts and Sciences of Ohio University In partial fulfillment of the requirements for the degree Doctor of Philosophy Brenda F. Pinkerman March 2006 This dissertation entitled MENSTRUALLY RELATED AND NONMENSTRUAL MIGRAINES IN A FREQUENT MIGRAINE POPULATION: FEATURES, CORRELATES, AND ACUTE TREATMENT DIFFERENCES by BRENDA F. PINKERMAN has been approved for the Department of Psychology and the College of Arts and Sciences by Kenneth A. Holroyd Distinguished Professor of Psychology Benjamin M. Ogles Interim Dean, College of Arts and Sciences PINKERMAN, BRENDA F. Ph.D. March 2006. Clinical Psychology Menstrually Related and Nonmenstrual Migraines in a Frequent Migraine Population: Features, Correlates, and Acute Treatment Differences (307 pp.) Director of Dissertation: Kenneth A. Holroyd This research describes and compares menstrually related migraines as defined by recent proposed guidelines of the International Headache Society (IHS, 2004) to nonmenstrual migraines in a population of female migraineurs with frequent, disabling migraines. Migraines are compared by frequency per day of the menstrual cycle, headache features, use of abortive and rescue medications, and acute migraine treatment outcomes. In addition, this study explores predictors of acute treatment response and headache recurrence within 24 hours following acute migraine treatment for menstrually related migraines. Participants are 107 menstruating female migaineurs who met IHS (2004) proposed criteria for menstrually related migraines and completed headache diaries using hand-held computers. Diary data are analyzed using repeated measures logistic regression. The frequency of migraines is significantly increased during the perimenstrual period, and menstrually related migraines are of longer duration and greater frequency with longer lasting disability than nonmenstrual migraines.
    [Show full text]
  • First Reversals of Cognitive Decline in Alzheimer's Disease and Its
    1/12/2017 First Reversals of Cognitive Decline in Alzheimer’sSystems Therapeutics, Disease and its PresidentPrecursors, Obama, MCI and and the End ofSCI Alzheimer’s Disease Dale E. Bredesen, M.D. Augustus Rose Professor Easton Laboratories for Neurodegenerative Disease Research UCLA Founding President, Buck Institute “There is nothing that will prevent, reverse, or slow the progress of Alzheimer’s disease.” “Everyone knows someone who is a cancer survivor; no one knows an Alzheimer’s survivor.” 1 1/12/2017 30,000,000 patients in 2012 3rd leading cause (James, B. D. et al. Contribution of Alzheimer disease to mortality in the United States. Neurology 82, 1045-1050, doi:10.1212/WNL. 0240 (2014) Pres. Obama and NAPA, 2011 160,000,000 patients in 2050 2 1/12/2017 Women at the epicenter of the epidemic •65% of patients •60% of caregivers •More common than breast cancer 0 Cures 3 1/12/2017 Alzheimer’s Disease (AD) Therapeutic Landscape A production APPROVED A aggregation Donepezil (Aricept) A clearance Rivastigmine (Exelon) Tau aggregation/phosph Galantamine (Razadyne) Cholinergic drugs Tacrine (Cognex) Others Memantine (Namenda) PHASE 3 PHASE 2 PHASE 1 Solanezumab ELND005 PBT2 AL-108 GSK933776 NIC5-15 PF04360365 AF102B MABT5102A Bapineuzmab Valproate Bryostatin-1 Nicotinamide Talsaclidine EHT-0202 NP12 ACC001 UB311 Alzemed Antioxidant BMS708163 Lithium AN1792 R1450 Begacestat Semagacestat Statins ABT089 NGF CAD106 V950 PF3084014 AZD3480 SB742457 Flurizan Dimebon E2012 Huperzine-A PRX03140 CTS21166 Rosiglitazone EGCg EVP6124 PUFA MK0752 MEM3454 TTP448 Phenserine CHF5074 PF-04447943 Clinical Trial in AD terminated “Game of Throwns” (243/244) R.I.P. R.I.P. R.I.P.
    [Show full text]
  • Schwangerschaften Während Der Anwendung Kontrazeptiver Methoden
    Journal für Reproduktionsmedizin und Endokrinologie – Journal of Reproductive Medicine and Endocrinology – Andrologie • Embryologie & Biologie • Endokrinologie • Ethik & Recht • Genetik Gynäkologie • Kontrazeption • Psychosomatik • Reproduktionsmedizin • Urologie Schwangerschaften während der Anwendung kontrazeptiver Methoden - Eine Stellungnahme der Deutschen Gesellschaft für Gynäkologische Endokrinologie und Fortpflanzungsmedizin (DGGEF) e.V. und des Berufsverbands der Frauenärzte (BVF) e.V. Rabe T, Goeckenjan M, Dikow N, Schaefer C, Ahrendt HJ Mueck AO, Merkle E, Merki G, Egarter C, König K Albring C J. Reproduktionsmed. Endokrinol 2013; 10 (4), 214-234 www.kup.at/repromedizin Online-Datenbank mit Autoren- und Stichwortsuche Offizielles Organ: AGRBM, BRZ, DVR, DGA, DGGEF, DGRM, D·I·R, EFA, OEGRM, SRBM/DGE Indexed in EMBASE/Excerpta Medica/Scopus Krause & Pachernegg GmbH, Verlag für Medizin und Wirtschaft, A-3003 Gablitz FERRING-Symposium digitaler DVR 2021 Mission possible – personalisierte Medizin in der Reproduktionsmedizin Was kann die personalisierte Kinderwunschbehandlung in der Praxis leisten? Freuen Sie sich auf eine spannende Diskussion auf Basis aktueller Studiendaten. SAVE THE DATE 02.10.2021 Programm 12.30 – 13.20Uhr Chair: Prof. Dr. med. univ. Georg Griesinger, M.Sc. 12:30 Begrüßung Prof. Dr. med. univ. Georg Griesinger, M.Sc. & Dr. Thomas Leiers 12:35 Sind Sie bereit für die nächste Generation rFSH? Im Gespräch Prof. Dr. med. univ. Georg Griesinger, Dr. med. David S. Sauer, Dr. med. Annette Bachmann 13:05 Die smarte Erfolgsformel: Value Based Healthcare Bianca Koens 13:15 Verleihung Frederik Paulsen Preis 2021 Wir freuen uns auf Sie! Schwangerschaften während der Anwendung kontrazeptiver Methoden Schwangerschaften während der Anwendung kontrazeptiver Methoden* Eine Stellungnahme der Deutschen Gesellschaft für Gynäkologische Endokrinologie und Fortpflanzungsmedizin (DGGEF) e.V.
    [Show full text]
  • Eraas for Menopause Treatment: Welcome the ‘Designer Estrogens’
    REVIEW CME LEARNING OBJECTIVE: Readers will tailor hormone therapy to the needs of the patient CREDIT HEATHER D. HIRSCH, MD, MS, NCMP ELIM SHIH, MD, NCMP HOLLY L. THACKER, MD, NCMP Assistant Professor, Clinical Internal Medicine, Division Department of Obstetrics and Gynecology, Director of Center for Specialized Women’s Health, of General Internal Medicine, The Ohio State University, Women’s Health Institute, Cleveland Clinic Department of Obstetrics and Gynecology, Women’s Columbus, and Center for Women’s Health, Health Institute, Cleveland Clinic; Professor, Cleveland The Ohio State University Wexner Medical Center, Clinic Lerner College of Medicine of Case Western Upper Arlington, OH Reserve University, Cleveland, OH ERAAs for menopause treatment: Welcome the ‘designer estrogens’ ABSTRACT strogen receptor agonist-antagonists E(ERAAs), previously called selective es- Estrogen receptor agonist-antagonists (ERAAs) selec- trogen receptor modulators (SERMs), have tively inhibit or stimulate estrogen-like action in targeted extended the options for treating the vari- tissues. This review summarizes how ERAAs can be used ous conditions that menopausal women suffer in combination with an estrogen or alone to treat meno- from. These drugs act differently on estrogen pausal symptoms (vasomotor symptoms, genitourinary receptors in different tissues, stimulating re- syndrome of menopause), breast cancer or the risk of ceptors in some tissues but inhibiting them breast cancer, osteopenia, osteoporosis, and other female in others. This allows selective inhibition or midlife concerns. stimulation of estrogen-like action in various target tissues.1 KEY POINTS This article highlights the use of ERAAs Tamoxifen is approved to prevent and treat breast cancer. to treat menopausal vasomotor symptoms It may also have beneficial effects on bone and on car- (eg, hot flashes, night sweats), genitourinary diovascular risk factors, but these are not approved uses.
    [Show full text]
  • 1614598183048 Newsrai
    SANREMO “70 + 1” Il Festival 2021, ancora più musica Musica, sempre di più. E con tutte le sfumature proposte dai 26 Campioni in gara, ai quali si aggiungo- no le 8 Nuove Proposte. Il 71° Festival di Sanremo (anzi, il “70 + 1”) firmato dal Direttore Artistico Ama- deus va in scena: cinque appuntamenti, dal 2 al 6 marzo in prima serata su Rai1, Radio2 e RaiPlay, in diretta da un Teatro Ariston completamente trasformato dalla scenografia di Gaetano e Chiara Ca- stelli, mentre la regia – tra tradizione e sperimentazione - è firmata da Stefano Vicario. Ad affiancare Amadeus sul palco dell’Ariston, ci saranno Fiorello, Zlatan Ibrahimovic, Achille Lauro, Matilda De An- gelis, Elodie, Vittoria Ceretti, Barbara Palombelli e altri grandi ospiti dal mondo della musica e non solo. Come sempre, i cantanti saranno accompagnati dall’Orchestra del Festival - composta da musicisti professionisti in parte scelti dalla Rai e in parte messi a disposizione dalla Fondazione Orchestra Sin- fonica di Sanremo – e dai coristi. “Io, Fiorello e tutte le persone che lavorano con noi – dice Amadeus - siamo sicuri che sarà un San- remo da ricordare, in un anno tra i più difficili della nostra vita, con la voglia di ripartire e di regalare al pubblico a casa qualcosa di unico. Il Festival di Sanremo ci appartiene, appartiene al costume e alla musica di questo Paese. Anche tra mille difficoltà: ‘La musica non si ferma mai‘. Lo spettacolo sta per iniziare!”. I 26 Campioni parteciperanno ciascuno con una canzone inedita e si esibiranno a gruppi di 13 nella prima e nella seconda serata del Festival.
    [Show full text]
  • Aldrich Raman
    Aldrich Raman Library Listing – 14,033 spectra This library represents the most comprehensive collection of FT-Raman spectral references available. It contains many common chemicals found in the Aldrich Handbook of Fine Chemicals. To create the Aldrich Raman Condensed Phase Library, 14,033 compounds found in the Aldrich Collection of FT-IR Spectra Edition II Library were excited with an Nd:YVO4 laser (1064 nm) using laser powers between 400 - 600 mW, measured at the sample. A Thermo FT-Raman spectrometer (with a Ge detector) was used to collect the Raman spectra. The spectra were saved in Raman Shift format. Aldrich Raman Index Compound Name Index Compound Name 4803 ((1R)-(ENDO,ANTI))-(+)-3- 4246 (+)-3-ISOPROPYL-7A- BROMOCAMPHOR-8- SULFONIC METHYLTETRAHYDRO- ACID, AMMONIUM SALT PYRROLO(2,1-B)OXAZOL-5(6H)- 2207 ((1R)-ENDO)-(+)-3- ONE, BROMOCAMPHOR, 98% 12568 (+)-4-CHOLESTEN-3-ONE, 98% 4804 ((1S)-(ENDO,ANTI))-(-)-3- 3774 (+)-5,6-O-CYCLOHEXYLIDENE-L- BROMOCAMPHOR-8- SULFONIC ASCORBIC ACID, 98% ACID, AMMONIUM SALT 11632 (+)-5-BROMO-2'-DEOXYURIDINE, 2208 ((1S)-ENDO)-(-)-3- 97% BROMOCAMPHOR, 98% 11634 (+)-5-FLUORODEOXYURIDINE, 769 ((1S)-ENDO)-(-)-BORNEOL, 99% 98+% 13454 ((2S,3S)-(+)- 11633 (+)-5-IODO-2'-DEOXYURIDINE, 98% BIS(DIPHENYLPHOSPHINO)- 4228 (+)-6-AMINOPENICILLANIC ACID, BUTANE)(N3-ALLYL)PD(II) CL04, 96% 97 8167 (+)-6-METHOXY-ALPHA-METHYL- 10297 ((3- 2- NAPHTHALENEACETIC ACID, DIMETHYLAMINO)PROPYL)TRIPH 98% ENYL- PHOSPHONIUM BROMIDE, 12586 (+)-ANDROSTA-1,4-DIENE-3,17- 99% DIONE, 98% 13458 ((R)-(+)-2,2'- 963 (+)-ARABINOGALACTAN BIS(DIPHENYLPHOSPHINO)-1,1'-
    [Show full text]
  • NDA/BLA Multi-Disciplinary Review and Evaluation
    NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) NDA/BLA Multi-Disciplinary Review and Evaluation Application Type NDA Application Number(s) NDA 214154 (IND 110682) Priority or Standard Standard Submit Date(s) April 15, 2020 Received Date(s) April 15, 2020 PDUFA Goal Date April 15, 2021 Division/Office Division of Urology, Obstetrics, and Gynecology (DUOG) / Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine (ORPURM) Review Completion Date April 15, 2021 Established/Proper Name drospirenone and estetrol tablets (Proposed) Trade Name Nextstellis Pharmacologic Class Combination hormonal contraceptive Applicant Mayne Pharma LLC Dosage form Tablet Applicant proposed Dosing x Take one tablet by mouth at the same time every day. Regimen x Take tablets in the order directed on the blister pack. Applicant Proposed For use by females of reproductive potential to prevent Indication(s)/Population(s) pregnancy Recommendation on Approval Regulatory Action Recommended For use by females of reproductive potential to prevent Indication(s)/Population(s) pregnancy (if applicable) Recommended Dosing x Take one pink tablet (drospirenone 3 mg, estetrol Regimen anhydrous 14.2 mg) by mouth at the same time every day for 24 days x Take one white inert tablet (placebo) by mouth at the same time every day for 4 days following the pink tablets x Take tablets in the order directed on the blister pack 1 Reference ID: 4778993 NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) Table of Contents Table of Tables .................................................................................................................... 5 Table of Figures ................................................................................................................... 7 Reviewers of Multi-Disciplinary Review and Evaluation ...................................................
    [Show full text]
  • U.S. Medical Eligibility Criteria for Contraceptive Use, 2010
    Morbidity and Mortality Weekly Report www.cdc.gov/mmwr Early Release May 28, 2010 / Vol. 59 U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 Adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition department of health and human services Centers for Disease Control and Prevention Early Release CONTENTS The MMWR series of publications is published by the Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Introduction .............................................................................. 1 Disease Control and Prevention (CDC), U.S. Department of Health Methods ................................................................................... 2 and Human Services, Atlanta, GA 30333. How to Use This Document ......................................................... 3 Suggested Citation: Centers for Disease Control and Prevention. [Title]. MMWR Early Release 2010;59[Date]:[inclusive page numbers]. Using the Categories in Practice ............................................... 3 Recommendations for Use of Contraceptive Methods ................. 4 Centers for Disease Control and Prevention Contraceptive Method Choice .................................................. 4 Thomas R. Frieden, MD, MPH Director Contraceptive Method Effectiveness .......................................... 4 Peter A. Briss, MD, MPH Unintended Pregnancy and Increased Health Risk ..................... 4 Acting Associate Director for Science Keeping Guidance Up to Date ...................................................
    [Show full text]
  • Migraine: Spectrum of Symptoms and Diagnosis
    KEY POINT: MIGRAINE: SPECTRUM A Most patients develop migraine in the first 3 OF SYMPTOMS decades of life, some in the AND DIAGNOSIS fourth and even the fifth decade. William B. Young, Stephen D. Silberstein ABSTRACT The migraine attack can be divided into four phases. Premonitory phenomena occur hours to days before headache onset and consist of psychological, neuro- logical, or general symptoms. The migraine aura is comprised of focal neurological phenomena that precede or accompany an attack. Visual and sensory auras are the most common. The migraine headache is typically unilateral, throbbing, and aggravated by routine physical activity. Cutaneous allodynia develops during un- treated migraine in 60% to 75% of cases. Migraine attacks can be accompanied by other associated symptoms, including nausea and vomiting, gastroparesis, di- arrhea, photophobia, phonophobia, osmophobia, lightheadedness and vertigo, and constitutional, mood, and mental changes. Differential diagnoses include cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoenphalopathy (CADASIL), pseudomigraine with lymphocytic pleocytosis, ophthalmoplegic mi- graine, Tolosa-Hunt syndrome, mitochondrial disorders, encephalitis, ornithine transcarbamylase deficiency, and benign idiopathic thunderclap headache. Migraine is a common episodic head- (Headache Classification Subcommittee, ache disorder with a 1-year prevalence 2004): of approximately 18% in women, 6% inmen,and4%inchildren.Attacks Recurrent attacks of headache, consist of various combinations of widely varied in intensity, fre- headache and neurological, gastrointes- quency, and duration. The attacks tinal, and autonomic symptoms. Most are commonly unilateral in onset; patients develop migraine in the first are usually associated with an- 67 3 decades of life, some in the fourth orexia and sometimes with nausea and even the fifth decade.
    [Show full text]